NCT06874751Completed
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
Source: ClinicalTrials.gov · Last updated 21 May 2025
Brief summary (registry, in English)
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 45456 (actual)
- First submitted
- 8 Mar 2025
- Start date
- 6 Dec 2024
- Primary completion date
- 28 Mar 2025
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT06874751
What you commit to
- Study type: Observational
- Participants enrolled: 45456
- From 6 Dec 2024 to the primary completion date, 28 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with evidence of bariatric surgery
Other illness
- Participants with end-stage kidney disease (ESKD) including chronic or intermittent hemodialysis or peritoneal dialysis, kidney transplant, and/or record of estimate glomerular filtration rate less than (\<) 15 milliliter per minute per 1.73\*meter square (mL/min/1.73m\^2)
Lab values
- Participants with evidence of diabetes including more or equal to (≥)2 diagnoses of type 1 diabetes or more or equal to ( ≥) 2 diagnoses of type 2 diabetes on distinct dates, use of a glucose-lowering agent, and/or glycated hemoglobin (HbA1c) laboratory result above or equal to 6.5 percent (%)
Other
- Participants with a diagnosis of chronic or acute pancreatitis
- Participants with a diagnosis of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
- Pregnancy in female participants
- Use of a glucagon-like peptide-1 (GLP-1) or GLP-1/gastric inhibitory polypeptide (GIP) receptor ago-nist approved for weight management (excluding semaglutide 2.4 mg)
Who the study is looking for
- Participants with overweight or obesity defined as at least one overweight/obesity indication of a specified body mass index (BMI) above or equal to (≥) 27.0 kilogram per meter square (kg/m\^2) and undefined obesity/overweight indications, defined by diagnoses and laboratory values
- Participants with established ASCVD defined as a diagnosis of MI, diagnosis of ischemic stroke, and/or evidence of peripheral arterial disease
- Participants who are above or equal to (≥) 45 years old by the end of data availability
- Participants who initiated semaglutide 2.4 mg on or after the eligibility date and June4, 2021 (semaglutide 2.4 mg users) or participants with no evidence of semaglutide 2.4 mg usage (non-users) during January 1, 2016 to December 31, 2023
- Participant with continuous insurance enrolment eligibility above or equal to (≥)12 months prior to the index date
- Participants with re-confirmed overweight/obesity indication during the baseline period
Age in the registry: 45 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Plainsboro | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.